Delos Capital and AP Biosciences Launch Strategic Partnership to Accelerate Next-Generation Antibody Development
核心洞察
Delos Capital (搜索) and AP Biosciences (搜索) announced a first-of-its-kind collaboration between a specialist biotech venture firm and a publicly-traded biopharma to create and incubate new biotechnology companies.
The partnership combines Delos' company-building expertise with APBio's proprietary antibody discovery platforms to accelerate novel immune-related drug candidates through early clinical proof of concept.
Initial focus targets autoimmune diseases (搜索) using bi- and tri-specific antibody approaches that combine novel and de-risked targets and mechanisms.
Delos Capital (搜索) and AP Biosciences (搜索) announced a strategic collaboration on May 11, 2026, to create and incubate new biotechnology companies focused on discovering and developing novel immune-related drug candidates through early clinical proof of concept. The partnership represents a first-of-its-kind collaboration between a specialist biotech venture firm and a publicly-traded biopharma company.
Partnership Structure and Focus
The collaboration combines Delos Capital (搜索)'s track record in building and leading biotech companies with AP Biosciences (搜索)' fully integrated R&D capabilities and operational efficiency in Greater China. This model aims to enable faster and more capital-efficient translation from innovative concepts to clinical-stage assets.
Under the agreement, Delos will lead therapeutic ideation, financing, and strategic development through its Delos Foundry (搜索) initiative. AP Biosciences (搜索) will contribute its proprietary antibody discovery platform and translational expertise, drawing on its experience advancing molecules from discovery through pivotal Phase 3 clinical studies.
The parties' initial focus centers on autoimmune diseases (搜索) using bi- and tri-specific antibody approaches that combine novel and de-risked targets and mechanisms.
Leadership Perspectives
"Building and leading biotech companies is core to our team's identity at Delos, which is why we are pushing forward our Delos Foundry (搜索)," said Henry Chen, founder and managing partner of Delos Capital (搜索). "If we don't see existing companies that match one of our investment theses, our team can fill that gap by incubating innovative assets in a US-based NewCo. We are pleased to have a biologics design partner like APBio that can bring to bear the perspective of a biopharma with full-stack R&D experience."
Jeng Her, Ph.D., founder and Chief Executive Officer of AP Biosciences (搜索), added: "This collaboration allows us to extend the impact of our antibody discovery platforms beyond our internal pipeline. By pairing our biologics design capabilities with Delos' company-building expertise, we can help translate innovative therapeutic concepts into clinically validated programs through a capital-efficient and scalable model."
Company Capabilities
Delos Capital (搜索) operates as a life sciences investment firm that empowers life sciences leaders to turn bold ideas into medical breakthroughs for patients. The firm's team draws upon diverse skills built as operators and investors at top tier biotech organizations, with deep networks across significant biotech innovation hubs. Their investment process combines deep understanding of biology, proprietary AI workflows, unmet needs in medicine, and building high-performing companies.
AP Biosciences (搜索) is a Taiwan-based clinical-stage biopharmaceutical company committed to developing innovative antibody-based therapies for cancer (搜索) and other diseases. The company leverages its proprietary Omni-Mab and T-Cube platforms to pioneer next-generation bispecific antibodies (搜索) designed to enable precise, tumor-targeted immune activation. APBio's pipeline includes multiple clinical-stage programs, as well as partnered assets advancing through later stages of development.